Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Top Cited Papers
Open Access
- 31 May 2006
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 55 (3), 420-426
- https://doi.org/10.1002/art.21984
Abstract
Objective The frequency of many adverse events (AEs) associated with low‐dose glucocorticoid use is unclear. We sought to determine the prevalence of glucocorticoid‐associated AEs in a large US managed care population. Methods Using linked administrative and pharmacy claims, adults receiving ≥60 days of glucocorticoids were identified. These individuals were surveyed about glucocorticoid use and symptoms of 8 AEs commonly attributed to glucocorticoid use. Results Of the 6,517 eligible glucocorticoid users identified, 2,446 (38%) returned the mailed survey. Respondents were 29% men with a mean ± SD age of 53 ± 14 years; 79% were white and 13% were African American. Respondents had a mean ± SD of 7 ± 3 comorbid conditions and were prescribed a mean ± SD prednisone‐equivalent dosage of 16 ± 14 mg/day. More than 90% of individuals reported at least 1 AE associated with glucocorticoid use; 55% reported that at least 1 AE was very bothersome. Weight gain was the most common self‐reported AE (70% of the individuals), cataracts (15%) and fractures (12%) were among the most serious. After multivariable adjustment, all AEs demonstrated a strong dose‐dependent association with cumulative glucocorticoid use. Among users of low‐dose therapy (≤7.5 mg of prednisone per day), increasing duration of use was significantly associated with acne, skin bruising, weight gain, and cataracts. Conclusion The prevalence of 8 commonly attributed self‐reported glucocorticoid‐associated AEs was significantly associated with cumulative and average glucocorticoid dose in a dose‐dependent fashion. Physicians should be vigilant for glucocorticoid‐related AEs and should counsel patients about possible risks, even among low‐dose long‐term users.This publication has 32 references indexed in Scilit:
- The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysisOsteoporosis International, 2002
- Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialAnnals of Internal Medicine, 2002
- Public health impact of adverse bone effects of oral corticosteroidsBritish Journal of Clinical Pharmacology, 2001
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- Use of oral corticosteroids in the United KingdomQJM: An International Journal of Medicine, 2000
- A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effectsAnnals Of The Rheumatic Diseases, 1999
- Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritisThe Lancet, 1997
- Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional studyBMJ, 1996
- The Effect of Glucocorticoids on Joint Destruction in Rheumatoid ArthritisThe New England Journal of Medicine, 1995
- Effect of Corticosteroids on Cataract FormationAmerican Journal of Ophthalmology, 1980